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Abstract
Introduction This study was designed to investigate the
putative anxiolytic-like activity of ultra-low doses of
Gelsemium sempervirens (G. sempervirens), produced
according to the homeopathic pharmacopeia.
Methods Five different centesimal (C) dilutions of G.
sempervirens (4C, 5C, 7C, 9C and 30C), the drug buspirone
(5 mg/kg) and solvent vehicle were delivered intraperito-
neally to groups of ICR-CD1 mice over a period of 9 days.
The behavioral effects were assessed in the open-field (OF)
and light–dark (LD) tests in blind and randomized fashion.
Results Most G. sempervirens dilutions did not affect the
total distance traveled in the OF (only the 5C had an almost
significant stimulatory effect on this parameter), indicating
that the medicine caused no sedation effects or unspecific
changes in locomotor activity. In the same test, buspirone
induced a slight but statistically significant decrease in
locomotion. G. sempervirens showed little stimulatory
activity on the time spent and distance traveled in the
central zone of the OF, but this effect was not statistically
significant. In the LD test, G. sempervirens increased the %
time spent in the light compartment, an indicator of
anxiolytic-like activity, with a statistically significant effect
using the 5C, 9C and 30C dilutions. These effects were
comparable to those of buspirone. The number of tran-
sitions between the compartments of the LD test markedly
increased with G. sempervirens 5C, 9C and 30C dilutions.
Conclusion The overall pattern of results provides evidence
that G. sempervirens acts on the emotional reactivity of
mice, and that its anxiolytic-like effects are apparent, with a
non-linear relationship, even at high dilutions.
Keywords Gelsemium sempervirens.Animal models of
anxiety.Open-field test.Light–dark test.Ultra-low doses.
Complementary medicine.Gelsemine.Nanopharmacology
Introduction
Anxiety and behavioral disorders have a relatively high
prevalence in modern society and consume significant
financial resources. The most well-known tranquilisers or
anxiolytics are those of the benzodiazepine family, which act
by modulating the GABAergic receptors, but many others are
known, including buspirone and other drugs belonging to the
class of azaspirodecanedione compounds, which act as
agonists of the serotoninergic receptors (5-HT1A). However,
the clinical use of those drugs is not without its drawbacks,
particularlydue tothe riskofsideeffects suchaspsychomotor
impairment or potentiation of other central depressant
drugs (Lader 2008; Cloos and Ferreira 2009). What is
more, 25% of patients with anxiety disorders do not
respond sufficiently to first-line treatment (Schosser and
Kasper 2009). Benzodiazepines are not recommended for
long-term treatment of generalized anxiety disorders, due to
associated development of tolerance, cognitive and memory
changes, physical dependence and withdrawal reaction on
discontinuation (Allgulander et al. 2003). Natural remedies
possessing the same efficacy as conventional drugs, but
with fewer side effects, would thus be a valuable addition
to the treatment options for anxiety-related disorders.
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DOI 10.1007/s00213-010-1855-2However, the acceptance of alternative remedies has thus
far been hampered by the scarcity of pharmacological
studies elucidating their indications, limitations and
mechanisms of action (Mamtani and Cimino 2002;
Pilkington et al. 2006a, b).
In traditional Materia Medica, Gelsemium sempervirens
(G. sempervirens) is described as a remedy for a variety of
anxiety-like psychological and behavioral symptoms
(Boericke 1927; Barbancey 1987; Guermonprez 2006);
however, consistent evidence of its efficacy is lacking.
The plant, belonging to the Loganiaceae family, is a
twining vine native to warm temperate and tropical
America, from Guatemala to the southeastern United
States. All parts of this plant contain the toxic strychnine-
related alkaloids gelsemine, gelseminine and sempervirine
(Schun and Cordell 1987). Gelsemine has been identified as
the main urinary marker of Gelsemium exposure (Lai and
Chan 2009). Neurological signs characterized by marked
progressive weakness and convulsions culminating in death
have been observed in goats after ingestion of G. semper-
virens and ensuing toxicosis (Thompson et al. 2002); the
nectar is also toxic to honeybees (Irwin and Adler 2006). In
phytotherapy literature, G. sempervirens has been reported to
show sedative, analgesic and anti-seizure properties, though
the effective doses are unclear (Valnet 1992; Demarque et al.
1995; Peredery and Persinger 2004). However, it should be
noted that this last-mentioned protective effect against
convulsions was obtained using an extract mixed with
Scutellaria lateriflora and Datura stramonium.
G. sempervirens in high dilutions, prepared according to
the homeopathic pharmacopeia, has been investigated by
some authors, but the reported results are not always
consistent, chiefly due to uncertainty connected with the
methodology and a lack of statistical evaluations (Binsard
1979; Binsard et al. 1980; Sukul et al. 1986; Guillemain et
al. 1989). There have been two studies in which high
dilutions of G. sempervirens w e r ef o u n dt oh a v ea
preventive action against experimental stress (electric
shock) in mice (Bousta et al. 2001) and against convulsions
provoked by lithium and pilocarpine in rats (Peredery and
Persinger 2004). In recent trials in our laboratory, G.
sempervirens showed promising anxiolytic-like effects in
the open-field test and appeared to work even at high
dilutions (Bellavite et al. 2009a), but a systematic dose–
response study was not performed. There is accordingly
scope for further studies exploring the effects of G.
sempervirens in mouse models of emotional response,
and, in particular, for investigating the dose (or dilution)-
dependence of such effects.
Experimental investigations carried out on highly diluted
solutions have suffered from problems of replicability
between different laboratories (Bellavite et al. 2006a, b;
Witt et al. 2007). It is therefore important for any
preliminary results in this field to be confirmed and
consolidated through further investigations by independent
laboratories, using rigorous protocols and statistical evalua-
tions. We accordingly adopted a carefully defined protocol
and applied it to a series of experiments designed to test (a)
the null hypothesis that the effect of any drug dilution is
similar to that of the control vehicle and (b) whether any
dose dependence of the putative effects can be demonstrated.
We employed two well-validated models which explore
the behavior of mice in novel environments, namely the
open-field test (OF) and the light–dark choice test (LD),
to acquire various behavioral parameters used in neuro-
psychopharmacology for drug screening. The OF test
(Walsh and Cummins 1976; Simon et al. 1994;P r u ta n d
Belzung 2003; Lamprea et al. 2008)i sw i d e l yu s e da sa
test of locomotion since the mice are free to move in the
entire field, and the distance traveled during a fixed time
can be measured (Mi et al. 2005;d eA r a u j oe ta l .2009;
Vasconcelos et al. 2009). However, a detailed ethological
analysis of the OF test, including time spent and distance
traveled in the center/periphery of the field, makes it
possible not only to examine general activity but also to
detect specific effects of drugs on behavioral parameters
such as field exploration propensity and thigmotaxis
(Choleris et al. 2001; Ramos et al. 2008;F u k u s h i r oe ta l .
2009). The two-compartment LD model system (Crawley
and Goodwin 1980; Hascoet et al. 2001;B e l z u n ga n d
Griebel 2001;B o u r i ne ta l .2007) is one of the most
commonly used behavioral paradigms: classic anxiolytics
(benzodiazepines) as well as the newer anxiolytic-like
compounds (e.g. serotonergic drugs or drugs acting on
neuropeptide receptors) (Bourin and Hascoet 2003)a n d
natural compounds (Chen et al. 2004;d eA r a u j oe ta l .
2009) can be detected using this paradigm, since they
specifically increase the time spent in the lit compartment
and the number of exploratory transitions.
Our experiments were performed on unconditioned
responses, using ethologicallybased paradigms involving
spontaneous reactions to non-painful stimuli. Ethological
models were chosen both for ethical reasons and because
our aim was to mimic the natural conditions in which
behavior is influenced by emotional states of fear,
curiosity and anxiety. Ethological observations show that,
though rodents naturally tend to explore a novel environ-
ment, open fields and illuminated spaces are aversive to
them and hence counteract the normal behavioral
responses (Griebel et al. 1993;C l e m e n te ta l .2007). It is
conceivable that these two conflicting drives make the test
highly sensitive to even extremely weak stimuli, such
as one might expect from ultra-low doses of an active
substance. However, ethological models are subject to
inter-individual differences and variable behavioral base-
line levels (Bourin et al. 2007) so that great care must be
534 Psychopharmacology (2010) 210:533–545taken with variable parameters such as environment, handling
and testing.
In this work, we sought to investigate the widest possible
range of G. sempervirens dilutions compatible with the
technical constraints and the expected inter-subject vari-
ability. Accordingly, we tested the effects of low (4C and
5C), medium (7C and 9C) and high dilutions (30C) of the
plant extract. Dilutions such as the 4th and 5th centesimal
(4C–5C) dilutions from crude extracts are expected to
contain ultra-low concentrations of the purported active
ingredient, but still falling within the molecular range since
the dilution factor from the first ethanolic extract (mother
tincture) is 10
8–10
10 times. On the other hand, dilutions of
12C (10
24 times) or higher theoretically contain no
molecules of the mother tincture since the dilution factor
exceeds the Avogadro–Loschmidt limit (Sainte-Laudy and
Belon 2009).
Since we used extremely low doses of drugs, the animals
were treated using a chronic regimen of one i.p. injection
everyday for 8–9 days. As a positive control, we used
the 5-HT(1A) agonist buspirone, which is suitable for
chronic treatments, in a dose of 5 mg/kg, which is within
the dosage range usually employed to detect anxiolytic-
like activity in rodents (Cole and Rodgers 1994;M e r a l ie t
al. 2003;G r u n d m a n ne ta l .2007; Yamauchi et al. 2008).
Partial 5-HT1A agonists like buspirone produce anxiolytic
effects in rodents as assessed by the LD test, whereas
contrasting results have been reported with full 5-HT1A
receptor agonists like 8-hydroxy-2-(di-n-propylamino)-
tetralin (8-OH-DPAT) (Young and Johnson 1991a; Shimada
et al. 1995; Bilkei-Gorzo et al. 1998). The drug-treated
animal groups were compared with control groups treated
with solutions of the same vehicle used for preparing the
drug dilutions.
Materials and methods
Subjects and handling
Male mice 4–5 weeks old of the ICR-CD1 strain were
purchased from Charles River Laboratories (Lecco, Italy)
and allowed to acclimate for 2 weeks before testing in
a controlled (temperature 22±2°C, humidity 55%±5%)
animal facility. At the beginning of the treatments, the
bodyweight of animals was 30±3 g. For each experiment,
64 mice were randomly distributed, two per cage, in plastic
cages (size: 25×14×12 cm) and housed with food and
water available ad libitum, except during the brief testing
periods. Lights were on between 7 a.m. and 7 p.m. The
cages were placed in a housing rack consisting of four rows
of eight cages each arranged in such a way that cages
assigned to different experimental groups were uniformly
distributed along rows and columns. The sequence of the
groups—and hence the order of injection and testing—was
evenly alternated to guarantee similar intervals between
operations for the different groups over the course of the
experiment. Each animal was used only once in the same
test to avoid the confounding effects of learning and
habituation. All the experiments were conducted in accor-
dance with the Italian NIH policies on the use of animals in
research, and the testing procedures were independently
approved by the Animal Ethical Committee of the
Interdepartmental Centre for Animal Research (CIRSAL)
of Verona University and by the Italian Health Ministry.
Drugs
The drugs for this study were produced by Boiron
Laboratoires, Lyon (F), starting from a whole hydro-
alcoholic extract of G. sempervirens, which was diluted
100 times in 30% ethanol/distilled water to obtain the 1C
dilution. Subsequent serial 100× dilutions up to 29C were
then made in the same solvent using glass bottles. After
each dilution, the bottle was vigorously agitated using a
mechanical shaker. The 3C, 4C, 6C, 8C and 29C dilutions
were stored in the dark at room temperature. The content of
gelsemine—the principal alkaloid of G. sempervirens
(Fig. 1)—in the first hydroalcoholic extract was 0.021%
(w/v), corresponding to a concentration of 6.5×10
−4 mol/l.
The control solution (vehicle) was the same batch of 30%
ethanol/distilled water solution used to prepare the drug
dilutions.
Before being used in each experiment, 0.4-ml samples of
the solutions were added to 39.6 ml of distilled sterile and
apyrogenic water in a sterile 50-ml Falcon plastic tube,
closed with a plastic cap and manually shaken with 20
strong vertical strokes to obtain the final 4C, 5C, 7C, 9C
and 30C dilutions and control vehicle used for treatments,
with final ethanol concentration lowered to 0.3% (v/v).
Buspirone (Sigma, final dose of 5 mg/kg) was diluted in the
final vehicle solution (0.3% ethanol in distilled water). In
Fig. 1 A drawing of the G. sempervirens plant and the structure of its
major alkaloid gelsemine
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solutions, all the samples were then coded by an indepen-
dent person and the codes kept sealed inside an envelope
until all the tests and calculations were completed. The
solutions were distributed in 15-ml sterile Falcon plastic
tubes (4 ml/tube), wrapped in aluminum foil and stored
at +4°C until the day of use. Before using, each tube was
again manually shaken with 20 strokes. All procedures
were performed in sterile conditions and using sterile
disposable plasticware. The final solutions used for the
treatments were tested by gas chromatography and mass
spectroscopy for possible contamination with buspirone;
the results of these tests were negative.
Treatments
A minimum required sample size of n=42 subjects per
group was computed on the basis of previous experience
(Bellavite et al. 2009b) and assuming a pre-established
statistical power level of 0.9 and an alpha level of 0.05.
Since several doses had to be tested in parallel, the study
was conducted with six replications, each with a minimum
sample size of eight. Thus, in each experiment, mice were
randomized into eight groups of eight animals: five groups
were treated with the different G. sempervirens dilutions,
one group with buspirone and two groups with the vehicle
(control). Two groups of control vehicle-treated animals
were included both to obtain highly consistent reference
values for calculating the drug effects and to permit
comparison of two identical groups to determine the
between-group stability of the experimental setting.
All the experiments were performed between 09:00 and
14:00 (LD) and between 09:00 and 15:00 (OF). The
solutions were administered in the morning for nine
consecutive days (including on the last two days when the
animals were tested) by intraperitoneal (i.p.) injection
(0.3 ml/mice). The treatments were administered row by
row, and the behavioral tests started 30 min after drug
injections. The animals were tested individually in four
separate devices, allowing a complete set of up to 64 mice
( 8a n i m a l s × 8g r o u p s )t ob et e s t e dd u r i n ga4 –5h
experimental session.
Behavioral tests
The experiments were performed in the following order:
open-field (OF) exploration test on day one (8th day of
drug administration) and light–dark choice test (LD) on the
following day (9th day of drug administration). Just before
testing, the animals were allowed to acclimate to the room
inside their cages for 3 min after being moved from their
customary housing area. The operators stayed outside the
testing room during recording of the experimental sessions.
Aside from the treatment injections and testing, the animals
were not subjected to pain or other forms of emotional or
physical stress.
Open-field test
The OF test (Prut and Belzung 2003; Simon et al. 1994;
Walsh and Cummins 1976) was performed by placing an
animal for 10 min in an environment consisting of a 50×
50 cm black-painted wood platform with 25-cm high
surrounding walls illuminated with white light (100 lx).
To evaluate central exploratory propensity, the arena was
divided virtually into two parts, with a square central zone
having an area corresponding to 25% of the total area. The
apparatus was cleaned thoroughly with water and soft
disposable paper between trials, and with water and
detergent between experiments.
Light–dark test
The LD test (Bourin and Hascoet 2003; Chen et al. 2004;
Hascoet et al. 2001) apparatus used consisted of a small,
secure dark compartment (15×30 cm) and a large, aversive
illuminated compartment (30×30 cm). The two compart-
ments were separated by a partition with an opening (4×
4 cm) through which the animal could pass from one
compartment to the other. The aversive compartment was
illuminated with 200 lx. The animals were placed in the
center of the lit compartment facing the opening and left to
explore the space for a 5-min testing period. The number of
transitions between the light and dark compartments in the
LD test was also evaluated on the screen by an operator
who was unaware of the group assignment of the mice. The
apparatus was cleaned thoroughly between trials.
Video tracking
All the sessions were recorded with a video-tracking
camera (GZ-MG135, JVC, Japan) and stored on DVD. A
software program (“Smart” VTS system from PanLab,
Barcelona, E) was used to automatically trace the position
and movements of the animals and calculate the time spent
in different zones and the distance traveled. All behavioral
recordings were carried out with the observer unaware of
the treatment group assignment of the mice.
Statistics
All analyses were performed using the SPSS software,
version 17 (SPSS Inc., Chicago, IL, USA: http://www.spss.
com). All data are represented as mean ± SEM values. The
Shapiro–Wilk test indicated that the data obtained were
parametric. The groups were compared by two-way
536 Psychopharmacology (2010) 210:533–545analysis of variance, using the treatment group and the
experiment as the factors. Post hoc t tests were performed
assuming equal variances with least significant difference
(LSD) corrections to adjust for multiple comparisons.
The net effect of the drugs was calculated in standard-
ized form as a percentage relative to the mean values of all
the controls in each experiment (taken as zero effect)
according to the formula:
Testvalueof eachmouse=meantestvalueof 16controlmice ðÞ   1 ½ 
  100:
This allowed the effects observed in all the experiments
to be pooled, compared and statistically evaluated.
Results
Open-field test
The mean values of each OF experiment and the mean
values±S.E.M. of all experiments, with statistical evalua-
tions, are reported in Tables 1, 2 and 3. Table 1 shows the
total distance traveled in the whole of the open-field arena.
This parameter does not reflect changes in emotional
behavior, but is important for evaluating the total locomotor
activity of the animals during the 10-min trial. G.
sempervirens dilutions did not change these values as
compared with the untreated control animals, except for the
5C dilution which produced an increase in this parameter
that only narrowly missed statistical significance (p=
0.052). Buspirone caused a small, but statistically signifi-
cant (p=0.002), decrease in the total distance traveled in the
field, suggesting a possible sedative effect of this drug at
the dosage used.
The two major behavioral variables evaluated in the OF
test were the percentage time spent in the central zone of
the field (Table 2) and the distance traveled in the central
zone (Table 3). As shown in Table 1, there was significant
variability between experiments (p<0.001) but no interac-
tion between experiments and groups, indicating that any
observed drug effects were not influenced by inter-
experiment differences. In most of the experiments, some
G. sempervirens dilutions appeared to increase the time
spent in the central zone. The values of the group treated
with G. sempervirens 7C were higher than the mean of the
controls in all experiments, while those of the 9C group
were higher in all cases but one (experiment no. 6).
However, global ANOVA for the groups yielded a value
of only p=0.063, precluding post hoc analysis to evaluate
the statistical significance of individual dilutions. The
experiments did not reveal any clear and reproducible
dose-dependence relations. The standard drug buspirone
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Psychopharmacology (2010) 210:533–545 537had little or no effect on the time spent in the central zone.
Similar results were observed for the distance traveled in
the center of the OF (Table 3): G. sempervirens 5C, 7C, 9C
and 30C showed a slight tendency to increase the distance
traveled in the central zone, while buspirone tended to
decrease the same parameter; however the magnitude of
these effects did not reach the threshold of statistical
significance.
Light–dark test
The mean values of each LD experiment and the mean
values±S.E.M. of all experiments, with statistical evalua-
tions, are reported in Tables 4 and 5. Also in this test, there
was a significant difference between experiments (p=
0.002) but no interaction between groups and experiments.
In the LD test, most G. sempervirens dilutions and the
conventional anxiolytic reference drug proved to be
significantly effective (global ANOVA for groups p=
0.002 and p=0.001 for the data of Tables 4 and 5,
respectively). The percentage time spent in the illuminated
compartment (Table 4) was significantly increased by the
5C and 9C G. sempervirens dilutions, while 30C exhibited
a borderline significance. The 9C dilution had a greater
effect than the mean of the controls in all experiments and
showed the highest statistical significance (p<0.001).
However, no clear dose-dependence relation was apparent
in this series of experiments. The standard drug buspirone
increased the time spent in the illuminated compartment, as
expected, thus confirming the sensitivity of the test.
The results for the number of transitions between
compartments (Table 5) showed a similar stimulatory effect
of G. sempervirens dilutions. However, buspirone, com-
pared to the control, had a lesser effect on the number of
transitions than it had on the time spent in the lit
compartment. Since the number of transitions are depen-
dent on locomotor activity, this may be related to a small
sedative effect, as also observed in the OF test.
The importance of the anxiolytic-like effects of G.
sempervirens in this test is reinforced by the observation
that the two separate groups treated with the control vehicle
produced similar scores, and both were different from those
of the verum-treated groups.
Summary of percentage effects
The results of all the experiments were pooled after
standardizing the values for each mouse with respect to
the mean value for the control mice of that experiment. The
differences between each control vehicle-treated mouse,
relative to the mean value of all the controls in the same
experiment, were also computed. This made it possible to
evaluate the variation between the two control groups and
the stability of the system. A summary of the main results
of this investigation is provided in Fig. 2. The mean
percentage effect value for all the mice in the treated groups
clearly shows a small increase due to G. sempervirens
dilutions in the OF paradigm (panels A and B). In the OF,
the G. sempervirens-treated animals (5C, 7C, 9C and 30C)
exhibited 10–20% higher activity than the control. However,
due to inter-individual variability of responses, these effects
did not attain statistical significance in global ANOVA
analysis. Buspirone had small, non-significant, effect on
the amount of time spent in the center (panel A) and
showed a tendency to inhibit the distance traveled in the
center (panel B).
G. sempervirens treatment caused a markedly significant
increase in the parameters of the LD paradigm (panels C
and D). Here, the most active G. sempervirens solutions
(5C, 9C and 30C) increased the parameters, considered to
be a sign of reduced anxiety, by 20–40%. With respect to
time spent in the light compartment, this effect was
comparable to that of buspirone, while in terms of the
number of transitions, the effect of G. sempervirens 9C and
30 C was much higher and more significant than that of
buspirone. This was probably due to a sedative effect of
Table 2 Permanence time in the center area of open field (% of total time)
Exp. no. Mean of controls Gels 4 Gels 5 Gels 7 Gels 9 Gels 30 Buspirone Control-A Control-B
1 6.7 6.2 8.4 9.0 8.5 7.1 7.8 6.9 6.5
2 13.0 11.1 13.4 19.4 15.9 15.8 12.6 14.2 11.9
3 15.0 17.8 15.6 16.2 17.8 17.5 16.5 15.7 14.4
4 15.2 18.5 19.0 16.8 17.9 15.8 n.t. 16.7 13.7
5 17.5 13.8 16.3 18.3 19.1 18.2 14.7 18.1 16.8
6 14.3 11.2 14.8 16.4 12.5 17.8 19.4 14.9 13.6
No. of animals/group 96 48 48 48 48 48 40 48 48
Mean (S.E.M.) 13.6 (0.6) 13.1 (0.9) 14.6 (0.8) 16.0 (1.1) 15.3 (1.0) 15.4 (1.2) 14.2 (1.0) 14.5 (0.8) 12.8 (0.8)
ANOVA: for groups df=8, F=1.87, p=0.063; for experiments df=5, F=30.1, p<0.001; for groups*experiments df=39, F=0.75, p=0.858
n.t. not tested
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Psychopharmacology (2010) 210:533–545 539buspirone which reduced the movement speed of the mice,
an effect that was not observed using diazepam (1 mg/kg in
acute treatment) in a separate experiment done under the
same conditions (data not shown). The control groups A
and B showed, in the various experimental models, a
variability (positive and negative) relative to the mean that
did not exceed 5%, tending to support the conclusion that
the drug effects are real and not attributable to chance.
Table 5 Transitions between compartments of light–dark test (n/5 min)
Exp. no. Mean of controls Gels 4 Gels 5 Gels 7 Gels 9 Gels 30 Buspirone Control-A Control-B
1 5.6 5.6 5.1 5.1 6.8 9.2 5.9 6.5 4.7
2 6.5 6.6 9.6 6.3 10.4 8.2 8.0 6.6 6.4
3 7.2 9.5 8.6 9.6 9.5 6.5 6.9 6.7 7.6
4 6.4 7.3 7.4 7.7 9.5 11.5 n.t. 6.7 6.1
5 8.2 7.7 9.0 9.1 9.7 9.9 7.3 6.5 9.9
6 4.5 8.5 7.4 6.4 7.3 7.1 6.6 4.9 4.1
No. of animals/group 96 48 48 48 48 48 40 48 48
Mean (S.E.M.) 6.4 (0.4) 7.5 (0.6) 7.9 (0.6) 7.4 (0.5) 8.9 (0.6) 8.7 (0.6) 6.9 (0.4) 6.3 (0.5) 6.5 (0.6)
ANOVA: for groups df=8, F=3.29, p=0.001; for experiments df=5, F=5.08, p<0.001; for groups*experiments df=39, F=0.78, p=0.820
Post hoc
a – 0.096 0.034 0.152 <0.001 0.001 0.472 0.920 0.920
aPost hoc analysis (LSD) of the difference between the mean of each group with the mean of all controls
n.t. not tested
Fig. 2 Effects of G. sempervirens dilutions and of buspirone on OF (a
and b) and LD (c and d) behavioral parameters, expressed as
percentages±S.E.M. relative to the mean values for the vehicle-
treated, control animals. N=48 and 40 animals for G. sempervirens-
treated and buspirone-treated groups, respectively. Global ANOVA
values for these evaluations were: panel A for experiments df=5, F=
0.97, p=0.438; for groups df=8, F=1.89, p=0.060; panel B for
experiments df=5, F=2.72, p=0.020; for groups df=8, F=1.39, p=
0.196; panel C for experiments df=5, F=2.51, p=0.029; for groups
df=8, F=3.11, p=0.002; panel D for experiments df=5, F=2.97, p=
0.012, for groups df=8, F=3.35, p=0.001. All interactions between
groups and experiments were not significant. The p values (*p<0.05;
**p<0.001) are from LSD-post hoc analysis by two-way ANOVA,
comparing drug-treated groups or vehicle-treated groups (control
groups A and B) with the mean of the corresponding control,
vehicle-treated groups. LSD-post hoc analysis was not performed on
data of panels A and B because global ANOVA was beneath the
significance threshold
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Benzodiazepines have monopolized the anxiety market for
some 40 years, but their potential for tolerance and
dependence has stimulated interest in alternative anxio-
lytics. Attention has focused on drugs such as monoamine
oxidase inhibitors, tricyclic antidepressants, selective sero-
tonin reuptake inhibitors and the 5-HT1A partial agonist,
buspirone (Bandelow et al. 2002; Allgulander et al. 2003).
The challenge for the future is not only to find efficacious
treatments with an acceptable side-effect profile, but also to
determine the optimal compounds for each of the different
anxiety disorders. Recently, there has been increased
attention on the ways to cost effectively meet the demand
for treatment so as to contain health service expenditure
(Morgan and Jorm 2009). Anxiety and depression are
among the symptoms most frequently reported by patients
seeking complementary and alternative medical treatments,
homeopathy and natural remedies (Mathie and Robinson
2006; Thompson et al. 2008; Greeson et al. 2008; Guethlin
et al. 2009).
G. sempervirens is one of the classical remedies used in
complementary medicine for treating patients who exhibit
neurological anxiety-like symptoms. In traditional Materia
Medica (Boericke 1927), G. sempervirens is described as a
cure for a variety of neurological and behavioral symp-
toms such as general prostration, dizziness, drowsiness,
dullness, trembling, tired feeling, mental apathy, muscular
weakness, prostration, lack of muscular coordination,
general depression caused by heat of the sun, emotional
excitement, ill effects provoked by fear or exciting news
and so on. In summary, the action of the remedy is centerd
on the nervous system, and effects on anxiety-like
behavioral symptoms have been suggested (Barbancey
1987; Guermonprez 2006) but not proven. As in the case
of many other alternative remedies, evidence of clinical
and pre-clinical (laboratory and animal models) efficacy is
scarce or completely lacking (Carpenter and Neal 2005;
Pilkington et al. 2006a).
Our experiments provide firm evidence that various
G. sempervirens dilutions have an anxiolytic-like effect on
mice in the LD test, without any effects on the locomotor
component assayed by OF test. The effects of some of the
tested doses of G. sempervirens, namely 9C and 30C, on
the time spent in the lit area of the LD test were comparable
to or even better than those of the standard anxiolytic
buspirone.
In the OF paradigm, G. sempervirens produced a slight,
but not significant increase in the amount of time spent in
the center of the field, while buspirone did not have any
significant effects. A possible explanation for this scarcity
of results in the OF test could be that in the experimental
conditions of this investigation, this test was insufficiently
sensitive for detecting anxiety and drug-related anxiolytic
effects. Others have reported that anxiolytic treatments do
not in and of themselves increase exploration in the central
zone of the OF, but rather that they counteract stress-
induced inhibition of exploratory behavior (Bourin et al.
2007). Since our experimental setting did not involve prior
exposure to stress, it is possible that under such conditions
the response of the mice to the drugs was slight. This
interpretation appears consistent with that of Bousta et al.
(2001) who report some anxiolytic-like effects of G.
sempervirens in mice stressed by repeated electric shock,
but no effects on normal mice.
A further problem with interpreting the OF data of this
investigation arises from the significant reduction in the
unspecific locomotor component produced by buspirone,
whereas the G. sempervirens dilutions did not cause such
an effect. Buspirone was administered over a period of 8–
9 days in parallel with G. sempervirens on the grounds that
it is a standard reference drug suited to chronic treatments
since it does not develop the tolerance typical of benzodia-
zepines (Miller and Koff 1994; Khan and Haleem 2007). It
is possible that, at the doses used and in these particular
experimental conditions, buspirone might have induced a
serotoninergic syndrome that interfered with locomotor
activity and anxiolytic-like effects. Mild anxiolytic-like
effects accompanied by a reduction in measures of general
activity, produced by buspirone at doses of 2.5–5.0 mg/kg,
have been reported by others (Cole and Rodgers 1994). It
remains to be established whether lower doses of buspirone
might avoid causing this unwanted side effect whilst
maintaining their anxiolytic-like activity. In any case, the
doses used in this investigation fell within the mean range
of those commonly employed for detecting anxiolytic-like
effects in rodents (Costall et al. 1989; Young and Johnson
1991b; Merali et al. 2003; Harada et al. 2006; Young et al.
2006; Grundmann et al. 2007; Pogorelov et al. 2007;
Yamauchi et al. 2008). That said, given the tendency of
buspirone to produce general behavioral suppression, it
might be advisable in future research to employ a different
drug (e.g. water-soluble benzodiazepine) as a positive
control in similar experimental settings.
A comparison of the data for the two test models shows
that the anxiolytic-like effects of G. sempervirens and
buspirone were higher and more significant in the LD than
in the OF test. This difference may be due to a number of
reasons. A first possibility is that the two tests explore
distinct behavioral aspects that are affected in different
ways by the remedies, as also borne out by their differing
sensitivity to the conventional drug buspirone. The light/
dark box is widely used with rodents as a model for
screening anxiolytic or anxiogenic drugs, based on the
innate aversion of rodents to brightly lit areas and the
spontaneous exploratory behavior of rodents in response to
Psychopharmacology (2010) 210:533–545 541mild stressors—such as are novel environments and light
(Crawley and Goodwin 1980). Belzung and Griebel suggest
thatthelight–darktestandtheelevatedplus-mazearethemost
appropriate devices for assessing “state anxiety”, whereas the
free-exploratory paradigm can be used for “trait anxiety”
(Griebel et al. 1993; Belzung and Griebel 2001). However,
the open-field test is also used as a model of state anxiety
(Bourin et al. 2007), and there are few true trait-anxiety
animal models, with those in use relying on genetic
paradigms or chronic exposure to fear-provoking stimuli.
An alternative explanation is that testing the animals on
two successive days might have changed the baseline
anxiety level, and, hence, their response to the treatments.
It has been noted that the extent to which an anxiolytic
compound can facilitate exploratory activity depends on the
baseline level of anxiety in the control group (Hascoet et al.
2001). Since our experimental setting did not involve prior
exposure to stress and the mice were naïve to testing when
the OF test was performed on the first day of trials, it is
possible that in those conditions the response of the mice to
G. sempervirens was low because their level of basal
anxiety, as assessed by the OF test, was lower. The anxiety
level of the animals might have increased on the second day
of trials, and this could have induced a higher response to
the treatments in the LD test. Differences between the type
and severity of external stressors, and between the
experimental setups, might account for the high variability
of results reported under different experimental conditions
and by different laboratories (Bourin et al. 2007).
The problem of dosage is obviously central to pharmacol-
ogy. From the pooled data of all the experiments, there
emerges clear and consistent evidence indicating that lower
dilutions (4C) were less effective (or entirely inactive on the
OF parameters) than higher dilutions (9C and 30C).
However, the pattern is much more complex since, in the
LD test where the most significant data were observed, the
7C and 30C dilutions showed lower effects than 5C and 9C,
respectively. A number of observations—coming from
several research fields (Belougne-Malfatti et al. 1998;B r o w n
and Ennis 2001; Marotta et al. 2003; Belon et al. 2004;
Eizayaga et al. 2005; Bellavite et al. 2006b;W i t te ta l .2007;
Ruiz-Vega and Estevez-Delgado 2008; Chirumbolo et al.
2009)—suggest that in high-dilution pharmacology, there is
no linear or proportional relation between the molecular
concentration of active substances and the therapeutic effect.
Thus far there is no satisfactory or unifying theoretical
explanation for these claims, though some hypotheses
suggest a role of the nano-heterogeneous structures and
dynamics of the solvent water (or water–ethanol) on a
mesoscopic scale (Arani et al. 1995; Del Giudice and
Preparata 1998;S m i t h2004) and/or of epitaxy (Demangeat
et al. 2004;E l i ae ta l .2004, 2007;M a s t r a n g e l o2007;R a oe t
al. 2007; Chaplin 2007;D e m a n g e a t2009).
A possible neurological target of G. sempervirens in
high dilutions has recently been identified by studies
showing that gelsemine, the main component of G.
sempervirens, stimulates biosynthesis of allopregnanolone
(3α,5α-THP) in the central nervous system of rats through
activation of receptors for glycine (Gly-R) (Venard et al.
2008). More recently, the same group has shown that the
5C and 9C dilutions of G. sempervirens and of pure
gelsemine stimulate the synthesis of 3α,5α-THP in both the
hippocampus and the spinal marrow in vitro (Venard et al.
2009). A particularly interesting observation is that the
effects of G. sempervirens in vitro were blocked by
strychnine, a well-known selective inhibitor of glycinergic
receptors. Because allopreganolone endogenously synthe-
sized in the central nervous system significantly modulates
anxiety or nociceptive mechanisms through paracrine and
autocrinemodes(LeMelledoandBaker2004; Birzniece et al.
2006;P a p a d o p o u l o se ta l .2006; Patte-Mensah et al. 2006),
substances capable of stimulating 3α,5α-THP formation in
neural networks appear potentially interesting for the
development of effective anxiolytic or analgesic therapies.
To summarize, the results of this work show that some
dilutions within the investigated dose range of G. semper-
virens exert an anxiolytic-like effect on mice in the light/
dark test and, to a lesser extent, in open-field test. The
remedy was found to augment the exploratory tendency in
novel environments, without any effects on the motor
coordination or sedation of the animals. This is one of the
first traditional remedies, already empirically used in
human patients for symptoms correlated with anxiety, to
have been proven effective in experimental animals and for
which there are some hypotheses as to its molecular targets
in the central nervous system.
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